Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real-World Experience from 554 sequential core biopsies from a single centre

Eur J Haematol. 2021 Feb;106(2):267-272. doi: 10.1111/ejh.13545. Epub 2020 Dec 2.

Abstract

Introduction: Whilst excision biopsy is traditionally preferred, advances in radiological and histological techniques warrant a re-look at core biopsy as a viable primary diagnostic method.

Method: Over a 3-year period, all patients who underwent core biopsy to investigate lymphoma at our centre were included.

Results: 554 consecutive patients were included (40.1% prior lymphoma and 59.4% new presentations). Three or more cores were taken in 420 (75.8%) cases. Median time from request to biopsy and biopsy to histology report was 2 (0-40) days and 7 (1-24) days, respectively. 510/544 (93.8%) biopsies were diagnostic. There was no difference in whether the biopsy was diagnostic based on indication (new vs. relapsed lymphoma) (P = .445), whether biopsy was PET-directed (P = .507), for T-cell lymphoma (P = .468) or nodal vs. extra-nodal (P = .693). Thirty-eight patients (6.9%) required a second biopsy due to inadequate tissue. In a patient experience survey, only 13.9% reported any complications (1 self-limiting minor bleeding, 4 bruising) whilst 16.7% reported any discomfort beyond 12 hours.

Conclusion: Core biopsy performed by experienced radiologists and analysed by expert haemato-pathologists is a reliable, well-tolerated method for diagnosing lymphoma and confirming relapse. Multiple cores can be obtained under local anaesthetic yielding sufficient material in the majority of cases.

Keywords: lymphoproliferative diseases; malignant lymphoma.

MeSH terms

  • Biopsy
  • Biopsy, Large-Core Needle* / methods
  • Biopsy, Large-Core Needle* / standards
  • Humans
  • Image-Guided Biopsy
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Lymphoproliferative Disorders / diagnosis*
  • Reproducibility of Results
  • Sensitivity and Specificity